Lanthanum dioxycarbonate

Drug Profile

Lanthanum dioxycarbonate

Alternative Names: RenaZorb; RZB-014; SPI-014 - Spectrum

Latest Information Update: 09 Jan 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Altair Nanotechnologies
  • Developer Spectrum Pharmaceuticals
  • Class Hyperphosphataemia therapies; Lanthanoid series elements; Small molecules
  • Mechanism of Action Phosphate binding protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Hyperphosphataemia

Most Recent Events

  • 24 Sep 2014 Biomarkers information updated
  • 07 Jan 2013 Lanthanum dioxycarbonate is available for licensing worldwide, particulary in Japan & in other Asian countries
  • 07 Jan 2013 Top-line adverse events & pharmacodymics data from a phase I trial in Healthy volunteers released by Spectrum Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top